BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO.B - US0905721082 - Common Stock
310.7 USD
-3.7 (-1.18%)
Overall BIO.B gets a fundamental rating of 4 out of 10. We evaluated BIO.B against 58 industry peers in the Life Sciences Tools & Services industry. BIO.B is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO.B has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BIO.B had positive earnings in the past year.
BIO.B had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
In the past 5 years BIO.B always reported a positive cash flow from operatings.
1.2 Ratios
BIO.B has a Return On Assets (-6.97%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -10.03%, BIO.B is in line with its industry, outperforming 53.45% of the companies in the same industry.
BIO.B has a better Return On Invested Capital (2.26%) than 62.07% of its industry peers.
BIO.B had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 13.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
The Operating Margin of BIO.B (10.27%) is better than 70.69% of its industry peers.
BIO.B's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 52.42%, BIO.B is doing good in the industry, outperforming 62.07% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO.B is destroying value.
BIO.B has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BIO.B has been reduced compared to 5 years ago.
Compared to 1 year ago, BIO.B has a worse debt to assets ratio.
2.2 Solvency
BIO.B has an Altman-Z score of 3.42. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
BIO.B has a better Altman-Z score (3.42) than 65.52% of its industry peers.
BIO.B has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO.B would need 3.57 years to pay back of all of its debts.
BIO.B has a Debt to FCF ratio of 3.57. This is in the better half of the industry: BIO.B outperforms 77.59% of its industry peers.
BIO.B has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
BIO.B's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO.B outperforms 58.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.42 |
ROIC/WACC0.23
WACC9.79%
2.3 Liquidity
A Current Ratio of 5.44 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B's Current ratio of 5.44 is amongst the best of the industry. BIO.B outperforms 84.48% of its industry peers.
A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B has a better Quick ratio (3.94) than 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased by -1.90% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
BIO.B shows a decrease in Revenue. In the last year, the revenue decreased by -0.88%.
BIO.B shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
Based on estimates for the next years, BIO.B will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.66%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.14, the valuation of BIO.B can be described as expensive.
Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than 70.69% of the companies in the same industry.
BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.98, which is the current average of the S&P500 Index.
BIO.B is valuated quite expensively with a Price/Forward Earnings ratio of 29.77.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 70.69% of the companies listed in the same industry.
BIO.B's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 35.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIO.B indicates a rather cheap valuation: BIO.B is cheaper than 82.76% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.97 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.85
EPS Next 2Y0.61%
EPS Next 3Y4.05%
5. Dividend
5.1 Amount
BIO.B does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (11/17/2025, 8:04:00 PM)
310.7
-3.7 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.73%
Inst Owner Change35.42%
Ins Owners3.84%
Ins Owner ChangeN/A
Market Cap8.41B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target363.55 (17.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-1.58%
PT rev (3m)-1.58%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)5.44%
EPS NY rev (1m)4.11%
EPS NY rev (3m)19.05%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)3.42%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)2.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.77 | ||
| P/S | 3.29 | ||
| P/FCF | 24.97 | ||
| P/OCF | 17.11 | ||
| P/B | 1.25 | ||
| P/tB | 1.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.32%
EPS(NY)10.44
Fwd EY3.36%
FCF(TTM)12.44
FCFY4%
OCF(TTM)18.16
OCFY5.85%
SpS94.51
BVpS248.96
TBVpS213.22
PEG (NY)N/A
PEG (5Y)3.85
Graham Number240.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.42 |
F-Score5
WACC9.79%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.54%
EBIT Next 3Y15.21%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
What is the valuation status of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
What are the PE and PB ratios of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES -CL B (BIO.B) is 30.14 and the Price/Book (PB) ratio is 1.25.
What is the earnings growth outlook for BIO-RAD LABORATORIES -CL B?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES -CL B (BIO.B) is expected to decline by -1.6% in the next year.